C4 Therapeutics, Inc. (CCCC)
CCCC moved a median of -0.10% 30 minutes after news, and 0.00% by the close. How CCCC actually reacts to news — the realized, point-in-time move the market made, measured across 315 labeled events over the last three years with zero look-ahead.
CCCC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.16% | 42% | 315 |
| 30-min | -0.10% | 50% | 315 |
| 60-min | +0.60% | 54% | 315 |
| to close | 0.00% | 50% | 315 |
| Middle 50% of CCCC reactions | -2.35% to +2.41% |
|---|---|
| Median reaction (30-min) | -0.10% |
| Measured reactions | 315 |
Half of all C4 Therapeutics, Inc. news events land between -2.35% and +2.41% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CCCC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 20 | +4.36% | 60% | +14.56% |
| Coverage initiations | 15 | -0.76% | 13% | -0.88% |
| Rating reiterations | 22 | -0.04% | 46% | -0.72% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CCCC ranks against every other measured name →
That’s how CCCC usually reacts — get an email when it moves on news →Email me when CCCC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CCCC's baseline. Nothing else.
Recent CCCC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting | Press release | GlobeNewswire | +1.65% | -1.65% | |
| Form 8-K C4 Therapeutics, Inc. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | +1.65% | -1.65% | |
| C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting | Press release | GlobeNewswire | -1.04% | -2.35% | |
| C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -4.04% | +0.78% | |
| Form 10-Q C4 Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.04% | +0.78% | |
| Form 8-K C4 Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -4.04% | +0.78% | |
| Form 8-K C4 Therapeutics, Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +2.00% | +3.77% | |
| C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population | Press release | GlobeNewswire | -1.44% | +1.31% | |
| Form 8-K C4 Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | +1.31% | |
| C4 Therapeutics to Participate in Upcoming Conferences | Press release | GlobeNewswire | +1.58% | +3.80% | |
| C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.06% | -1.58% | |
| Form 8-K C4 Therapeutics, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | -8.78% | |
| C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +0.16% | +2.92% | |
| Form 10-Q C4 Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.16% | +2.92% | |
| Form 8-K C4 Therapeutics, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +2.92% | |
| Form ARS C4 Therapeutics, Inc. For: Apr 29 | SEC filing · Form ARS | SEC EDGAR | -1.82% | -6.57% | |
| Form DEF 14A C4 Therapeutics, Inc. For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | -1.82% | -6.57% | |
| Form DEFA14A C4 Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.82% | -6.57% | |
| Form 8-K C4 Therapeutics, Inc. For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -2.82% | -10.74% | |
| C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) | Press release | GlobeNewswire | -1.66% | +0.00% | |
| Form 8-K C4 Therapeutics, Inc. For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +0.00% | |
| C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma | Press release | GlobeNewswire | +4.28% | +4.67% | |
| C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -13.09% | |
| Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types | Press release | Canada Newswire | -4.19% | -2.26% | |
| C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -2.45% | -2.80% | |
| Form 10-K C4 Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.45% | -2.80% | |
| Form 8-K C4 Therapeutics, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -2.45% | -2.80% | |
| Form S-8 C4 Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.45% | -2.80% | |
| C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma | Press release | GlobeNewswire | -0.47% | +6.98% | |
| C4 Therapeutics to Participate in Upcoming March Conferences | Press release | GlobeNewswire | -0.47% | +6.98% | |
| C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.93% | +3.37% | |
| C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | -2.20% | -5.97% | |
| C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.39% | +2.39% | |
| C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways | Press release | GlobeNewswire | +4.31% | +0.43% | |
| Form 8-K C4 Therapeutics, Inc. For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | +4.31% | +0.43% | |
| Form EFFECT C4 Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.58% | -1.55% | |
| C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +0.00% | +0.41% | |
| Form S-3 C4 Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.50% | +2.50% | |
| C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +0.00% | +1.28% | |
| Form 10-Q C4 Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +1.28% | |
| Form 8-K C4 Therapeutics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.28% | |
| Precision Oncology Approaches Drive $312B Market Transformation | Press release | PR Newswire | +2.05% | -2.87% | |
| C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering | Press release | GlobeNewswire | +4.84% | +16.98% | |
| Form 8-K C4 Therapeutics, Inc. For: Oct 16 | SEC filing · Form 8-K | SEC EDGAR | +4.84% | +16.98% | |
| C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma | Press release | GlobeNewswire | +2.24% | -3.59% | |
| Form 8-K C4 Therapeutics, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +2.24% | -3.59% | |
| Form 8-K C4 Therapeutics, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | -20.91% | |
| C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting | Press release | GlobeNewswire | +2.12% | -20.91% | |
| Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market | Press release | Canada Newswire | -1.82% | -1.09% | |
| C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration | Press release | GlobeNewswire | -2.26% | +0.76% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CCCC section they belong to.
Where else CCCC is measured.
CCCC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is C4 Therapeutics, Inc.'s median reaction calculated?
Every labeled CCCC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 315 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CCCC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CCCC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.